Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancerAllarity maintains a cash balance of...
Day: November 18, 2024
Rectify Pharma Presents Preclinical Data Supporting Development of Lead Candidate RTY-694 at The Liver Meeting® 2024
RTY-694 increased protein levels and function of ABCB4 and BSEP in primary hepatocytes, two transporters that play a key role in...
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
Topline results expected in early January 2025CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a...
CBIH Strengthens Clinical Research Team in Preparation for Launch of Next-Generation Cannabinoid Solutions
HOUSTON, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) continues to invest in top-tier talent as...
Psychemedics Corporation Reminds Stockholders to Cast Their Votes for Upcoming Annual Meeting of Stockholders
DALLAS, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing, reminds its stockholders...
Michael Stevens, Liviniti CFO, Named to 2025 Chicago Titan 100
Accomplished business executives recognized for leadership, vision and passionNatchitoches, Louisiana--(Newsfile Corp. - November 18, 2024) - Liviniti is pleased to...
RESTEM Presents Phase 1 Data of its ULSC Program in Polymyositis/Dermatomyositis at ACR Convergence 2024
- Oral presentation at ACR highlights safety and efficacy data from the Phase 1 trial of umbilical cord outer lining-derived...
BioHarvest Sciences to Host Third Quarter 2024 Earnings Call on November 25 at 4:30 P.M. Eastern Time
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 18, 2024) - BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV)...
Helius Medical Technologies, Inc. Announces Exploration of Strategic Alternatives
NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company...
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on...
Glow Sauna Studios Beems Westward with Multi-Unit Expansion into Kansas City
KANSAS CITY, KS / ACCESSWIRE / November 18, 2024 / Glow Sauna Studios, a recognized leader in holistic wellness, is...
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD – The Liver Meeting® 2024
Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patients Both artificial intelligence (AI) and...
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)
HOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company...
Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024
– sdATEVs maintained sustained patency throughout the six-month study – – sdATEV was observed to recellularize with host cells and...
Epsom Salt Council Sponsors the Arthritis Foundation’s North Carolina Jingle Bell Runs to Benefit Critical Research Initiatives
The races will take place in Charlotte and Raleigh ahead of the holiday season CHARLOTTE, NC / ACCESSWIRE / November...
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and Maintenance Regimens...
Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis
Next generation product may increase gastrointestinal luminal concentration while limiting system exposure LAVAL, QC / ACCESSWIRE / November 18, 2024...
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome 122 patients with moderate to severe irritable bowel...
PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations from Canada’s Drug Agency and Quebec’s INESSS
LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE/TSX:BHC),...
genXtraits Inc. licenses Fulcrum™ toolkit from Pairwise to enable its technology platform for generation of high-value enhanced crops with dominant traits
ALAMEDA ISLAND, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- genXtraits Inc. (genXtraits) today announced that it has entered into an...